Omeros Corporation Company Profile (NASDAQ:OMER)

About Omeros Corporation (NASDAQ:OMER)

Omeros Corporation logoOmeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement. Omidria is derived from its PharmacoSurgery platform, which is designed for patients undergoing ophthalmological, arthroscopic, urological and other surgical procedures. Its PharmacoSurgery platform is based on low-dose combinations of the United States Food and Drug Administration (FDA) approved therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to inhibit preemptively inflammation and other problems caused by surgical trauma, and to provide clinical assistances both during and after surgery.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:OMER
  • CUSIP: 68214310
  • Web:
  • Market Cap: $959.63 million
  • Outstanding Shares: 43,940,000
Average Prices:
  • 50 Day Moving Avg: $20.20
  • 200 Day Moving Avg: $14.76
  • 52 Week Range: $7.20 - $27.09
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -37.02
  • P/E Growth: -0.18
Sales & Book Value:
  • Annual Revenue: $46.46 million
  • Price / Sales: 20.66
  • Book Value: ($1.10) per share
  • Price / Book: -19.85
  • EBIDTA: ($47,190,000.00)
  • Net Margins: -131.95%
  • Return on Assets: -65.10%
  • Debt-to-Equity Ratio: -1.67%
  • Current Ratio: 3.03%
  • Quick Ratio: 2.97%
  • Average Volume: 999,132 shs.
  • Beta: 3.52
  • Short Ratio: 16.43

Frequently Asked Questions for Omeros Corporation (NASDAQ:OMER)

What is Omeros Corporation's stock symbol?

Omeros Corporation trades on the NASDAQ under the ticker symbol "OMER."

How were Omeros Corporation's earnings last quarter?

Omeros Corporation (NASDAQ:OMER) posted its quarterly earnings data on Wednesday, May, 10th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.01. The company had revenue of $12.26 million for the quarter, compared to the consensus estimate of $13.32 million. The business's revenue for the quarter was up 65.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.54) EPS. View Omeros Corporation's Earnings History.

Where is Omeros Corporation's stock going? Where will Omeros Corporation's stock price be in 2017?

7 brokers have issued 12-month price targets for Omeros Corporation's shares. Their forecasts range from $8.63 to $75.00. On average, they expect Omeros Corporation's stock price to reach $32.66 in the next year. View Analyst Ratings for Omeros Corporation.

What are analysts saying about Omeros Corporation stock?

Here are some recent quotes from research analysts about Omeros Corporation stock:

  • 1. According to Zacks Investment Research, "Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. " (7/18/2017)
  • 2. Cantor Fitzgerald analysts commented, "Omeros announced that it received breakthrough therapy designation for its MASP-2 inhibitor, OMS721, for the treatment of IgA nephropathy (IgAN)." (6/13/2017)
  • 3. Wedbush analysts commented, "The Wedbush View: With an emerging pipeline of rare disease focused products and OMIDRIA sales offsetting the company’s burn, we believe OMER to be an attractive investment for investors with a 2017-2018 horizon." (5/10/2017)
  • 4. Maxim Group analysts commented, "Omeros announced a case report describing resolution of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) in a dialysis- and transfusion-dependent adolescent girl who was treated with OMS721 under a compassionate-use protocol. The presentation 'Resolution of acute kidney injury secondary to TA-TMA by the anti-MASP-2 monoclonal antibody OMS721 in a pediatric HSCT recipient' occurred at the 43rd Annual Meeting of the European Society for Blood and Marrow Transplantation in Marseille, France on Monday, March 27, 2017. OMS721 continues to demonstrate positive data across multiple indications that are associated with complement. What differentiates OMS721 from other complement inhibitors like Alexion's Soliris, is the ability to target just a single arm of the complement system (lectin pathway) which leaves the rest of the system intact for important functions like protecting against infections." (3/27/2017)
  • 5. Needham & Company LLC analysts commented, "OMER's 4Q16 results, driven by Omidria sales that slightly bested consensus, came slightly ahead of Street expectations. Omidria sales are now annualizing at ~$52MM, which gives us confidence that sales can ramp up to the mid-$60MM range in 2017. Our concern with Omidria rests with the transitional passthrough reimbursement that potentially expires on 1/1/2018. If reimbursement is not extended, Omidria will likely be reimbursed as part of a procedural bundled payment, which would likely impact its current price. On the pipeline front, the OMS721 ph 3 trial for aHUS is now open for enrollment. We continue to view the pipeline (esp. OMS721) as a key value growth driver for OMER, though one that requires additional clinical data for validation. We maintain our Buy rating and adjust our PT to $22 (from $24)." (3/17/2017)

Who are some of Omeros Corporation's key competitors?

Who are Omeros Corporation's key executives?

Omeros Corporation's management team includes the folowing people:

  • Gregory A. Demopulos M.D., Chairman of the Board, President, Chief Executive Officer
  • Michael A. Jacobsen, Chief Accounting Officer, Vice President - Finance, Treasurer
  • Marcia S. Kelbon J.D., Vice President - Patent, General Counsel, Secretary
  • Thomas J. Cable, Lead Independent Director
  • Peter A. Demopulos M.D., Director
  • Ray Aspiri, Independent Director
  • Arnold C. Hanish, Independent Director
  • Leroy E. Hood M.D., Ph.D., Independent Director

Who owns Omeros Corporation stock?

Omeros Corporation's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Capital Impact Advisors LLC (0.16%) and Bank of Montreal Can (0.11%). Company insiders that own Omeros Corporation stock include Gregory A Md Demopulos, Marcia S Kelbon, Michael A Jacobsen, Peter A Md Demopulos and Thomas J Cable. View Institutional Ownership Trends for Omeros Corporation.

Who sold Omeros Corporation stock? Who is selling Omeros Corporation stock?

Omeros Corporation's stock was sold by a variety of institutional investors in the last quarter, including Capital Impact Advisors LLC and Bank of Montreal Can. Company insiders that have sold Omeros Corporation stock in the last year include Gregory A Md Demopulos, Marcia S Kelbon, Michael A Jacobsen and Thomas J Cable. View Insider Buying and Selling for Omeros Corporation.

How do I buy Omeros Corporation stock?

Shares of Omeros Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Omeros Corporation's stock price today?

One share of Omeros Corporation stock can currently be purchased for approximately $21.84.

MarketBeat Community Rating for Omeros Corporation (NASDAQ OMER)
Community Ranking:  3.6 out of 5 (  )
Outperform Votes:  330 (Vote Outperform)
Underperform Votes:  123 (Vote Underperform)
Total Votes:  453
MarketBeat's community ratings are surveys of what our community members think about Omeros Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Omeros Corporation (NASDAQ:OMER) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $32.66 (49.55% upside)

Analysts' Ratings History for Omeros Corporation (NASDAQ:OMER)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/14/2017WBB SecuritiesReiterated RatingStrong-Buy$75.00HighView Rating Details
6/14/2017WedbushReiterated RatingOutperform$47.00HighView Rating Details
6/13/2017Maxim GroupSet Price TargetBuy$23.00HighView Rating Details
6/13/2017Cantor FitzgeraldSet Price TargetHold$15.00HighView Rating Details
6/3/2017Cowen and CompanyReiterated RatingOutperformMediumView Rating Details
4/1/2017FBR & CoReiterated RatingBuyLowView Rating Details
3/17/2017Needham & Company LLCReiterated RatingBuy -> Buy$24.00 -> $22.00HighView Rating Details
10/17/2016S&P Equity ResearchBoost Price Target$7.65 -> $8.63N/AView Rating Details
8/19/2015Roth CapitalReiterated RatingBuy$38.00N/AView Rating Details
8/11/2015MLV & Co.Reiterated RatingBuy$38.00N/AView Rating Details
(Data available from 7/21/2015 forward)


Earnings History for Omeros Corporation (NASDAQ:OMER)
Earnings by Quarter for Omeros Corporation (NASDAQ:OMER)
Earnings History by Quarter for Omeros Corporation (NASDAQ OMER)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($0.35)($0.34)$13.32 million$12.26 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.40)($0.34)$11.64 million$11.30 millionViewListenView Earnings Details
8/9/2016Q216($0.50)($0.32)$9.80 million$10.00 millionViewListenView Earnings Details
5/10/2016Q116($0.43)($0.54)$8.79 million$7.40 millionViewListenView Earnings Details
3/8/2016Q415($0.53)($0.52)$5.35 million$6.66 millionViewListenView Earnings Details
11/9/2015Q315($0.47)($0.46)$7.97 million$3.30 millionViewListenView Earnings Details
8/10/2015Q215($0.56)($0.44)$2.86 million$3.20 millionViewListenView Earnings Details
5/11/2015Q115($0.63)($0.51)$0.15 million$0.39 millionViewListenView Earnings Details
3/16/2015Q4($0.62)($0.61)$0.15 million$0.18 millionViewListenView Earnings Details
11/10/2014Q114($0.59)($0.54)$0.43 million$0.21 millionViewN/AView Earnings Details
8/11/2014Q2($0.56)($0.53)$0.37 million$0.45 millionViewN/AView Earnings Details
5/12/2014Q1($0.45)($0.45)$0.45 million$0.10 millionViewN/AView Earnings Details
3/13/2014Q413($0.38)($0.05)$0.17 million$1.70 millionViewN/AView Earnings Details
11/7/2013Q313($0.44)($0.46)$0.14 million$0.20 millionViewN/AView Earnings Details
8/9/2013Q213($0.38)($0.48)$1.19 million$0.14 millionViewN/AView Earnings Details
5/10/2013Q1 2013($0.39)($0.40)$1.39 million$1.10 millionViewN/AView Earnings Details
3/18/2013($0.35)($0.30)$1.49 million$1.58 millionViewN/AView Earnings Details
11/9/2012Q312($0.34)($0.51)$1.42 million$1.40 millionViewN/AView Earnings Details
8/7/2012($0.36)($0.38)ViewN/AView Earnings Details
11/8/2011($0.39)($0.29)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Omeros Corporation (NASDAQ:OMER)
2017 EPS Consensus Estimate: ($1.12)
2018 EPS Consensus Estimate: $0.47
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.36)($0.34)($0.35)
Q2 20172($0.34)($0.30)($0.32)
Q3 20172($0.29)($0.21)($0.25)
Q4 20172($0.28)($0.12)($0.20)
Q1 20181($0.02)($0.02)($0.02)
Q2 20181$0.09$0.09$0.09
Q3 20181$0.16$0.16$0.16
Q4 20181$0.24$0.24$0.24
(Data provided by Zacks Investment Research)


Dividend History for Omeros Corporation (NASDAQ:OMER)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Omeros Corporation (NASDAQ:OMER)
Insider Ownership Percentage: 13.60%
Institutional Ownership Percentage: 45.44%
Insider Trades by Quarter for Omeros Corporation (NASDAQ:OMER)
Institutional Ownership by Quarter for Omeros Corporation (NASDAQ:OMER)
Insider Trades by Quarter for Omeros Corporation (NASDAQ:OMER)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/16/2017Michael A JacobsenVPSell12,000$24.95$299,400.00View SEC Filing  
6/15/2017Michael A JacobsenVPSell24,000$21.20$508,800.00View SEC Filing  
4/12/2017Thomas J CableDirectorSell3,000$16.49$49,470.00View SEC Filing  
12/7/2016Gregory A Md DemopulosCEOSell306,124$10.66$3,263,281.84View SEC Filing  
12/6/2016Gregory A Md DemopulosCEOSell102,040$10.80$1,102,032.00View SEC Filing  
12/5/2016Gregory A Md DemopulosCEOSell102,040$10.71$1,092,848.40View SEC Filing  
12/2/2016Gregory A Md DemopulosCEOSell306,120$11.58$3,544,869.60View SEC Filing  
9/15/2016Marcia S KelbonVPSell16,000$10.91$174,560.00View SEC Filing  
8/15/2016Marcia S KelbonVPSell15,900$11.56$183,804.00View SEC Filing  
7/15/2016Marcia S KelbonVPSell15,900$11.50$182,850.00View SEC Filing  
6/15/2016Marcia S KelbonVPSell15,900$11.42$181,578.00View SEC Filing  
5/16/2016Marcia S KelbonVPSell15,900$9.94$158,046.00View SEC Filing  
4/15/2016Marcia S KelbonVPSell15,900$15.18$241,362.00View SEC Filing  
3/24/2016Thomas J CableDirectorSell2,000$14.81$29,620.00View SEC Filing  
12/22/2015Marcia S. KelbonVPSell15,900$15.00$238,500.00View SEC Filing  
9/4/2015Peter A Md DemopulosDirectorBuy3,962$12.68$50,238.16View SEC Filing  
7/15/2015Thomas J CableDirectorSell2,000$18.78$37,560.00View SEC Filing  
3/24/2015Thomas J CableDirectorSell2,000$24.50$49,000.00View SEC Filing  
6/24/2014Peter A Md DemopulosDirectorBuy6,153$16.20$99,678.60View SEC Filing  
6/2/2014Thomas J CableDirectorSell5,000$11.80$59,000.00View SEC Filing  
7/3/2013Thomas J CableDirectorSell5,000$5.21$26,050.00View SEC Filing  
4/10/2013Thomas J CableDirectorSell5,000$3.98$19,900.00View SEC Filing  
1/4/2013Ray AspiriDirectorBuy40,000$5.72$228,800.00View SEC Filing  
1/3/2013Arnold C HanishDirectorBuy2,000$5.58$11,160.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Omeros Corporation (NASDAQ:OMER)
Latest Headlines for Omeros Corporation (NASDAQ:OMER)
DateHeadline logoToday's Research Reports on Stocks to Watch: Sorrento Therapeutics and Omeros Corporation - July 17 at 9:14 AM logoTechnical trading: These four stocks are breaking out of their pattern - July 12 at 11:11 AM logoOmeros Corporation (NASDAQ:OMER) Receives Consensus Rating of "Buy" from Brokerages - July 10 at 7:06 PM logoOmeros: It's Hard Enough To Succeed In Biotech Without False Attacks - July 9 at 7:44 PM logoOmeros' Pipeline Starting To Get The Recognition It Deserves - Seeking Alpha - July 8 at 1:17 PM logoBiotech Movers: BioCryst, Omeros, Radius Health - July 5 at 9:15 AM logoInvestors Purchase High Volume of Put Options on Omeros Corporation (OMER) - July 1 at 7:23 AM logoOmeros: Next Big Thing In Biotech - July 1 at 6:23 AM logoOmeros Corporation (OMER) Expected to Announce Quarterly Sales of $15.81 Million - June 30 at 1:04 PM logoOmeros Releases Statement in Response to Recent False Report - June 30 at 2:54 AM logoOmeros Corporation (OMER) Accuses Short Seller of Manipulation - June 30 at 2:54 AM logoOmeros to pursue legal action against short seller for report that shaved 21% off stock this week - June 30 at 2:54 AM logoOmeros threatens to sue anonymous detractor - June 30 at 2:54 AM logoHere's Why Omeros Corporation Fell as Much as 14.8% Today - Motley Fool - June 29 at 5:38 AM logoHere's Why Omeros Corporation Fell as Much as 14.8% Today - June 28 at 7:34 PM logoOmeros Corporation (OMER) Downgraded by BidaskClub to Hold - June 28 at 5:38 PM logoHere's Why Omeros Corporation Fell as Much as 14.8% Today - June 28 at 4:36 PM logo-$0.33 EPS Expected for Omeros Corporation (OMER) This Quarter - June 28 at 4:10 PM logoOmeros continues sell-off from recent 80% runup, shares retrace 23% in five days, bearish report making the rounds - June 28 at 3:49 PM logoThese 3 Biotech Stocks Have Doubled This Year; Can They Keep Climbing? - June 27 at 7:09 PM logoOmeros Corporation Forecasted to Post FY2018 Earnings of ($0.99) Per Share (OMER) - June 26 at 8:16 AM logoOmeros Corporation (OMER) Rating Lowered to Sell at Zacks Investment Research - June 24 at 12:36 PM logoOmeros Is Gaining Momentum With A Diverse Pipeline - Seeking Alpha - June 23 at 8:48 AM logoOmeros Corporation (OMER) Upgraded to "Buy" at BidaskClub - June 18 at 3:38 PM logoOmeros Corporation (OMER) PT Set at $15.00 by Cantor Fitzgerald - June 18 at 3:02 PM logoOmeros Corporation (OMER) Given a $23.00 Price Target at Maxim Group - June 18 at 3:02 PM logoOmeros Corporation (OMER) VP Michael A. Jacobsen Sells 12,000 Shares - June 16 at 10:17 PM logoOmeros (OMER) Hits New 52-Week High on Positive FDA Decision - Nasdaq - June 16 at 7:58 PM logoOmeros (OMER) Hits New 52-Week High on Positive FDA Decision - June 16 at 7:58 PM logo2 Longs And 2 Shorts To Watch - Benzinga - June 16 at 8:33 AM logoOmeros Corporation (OMER) VP Michael A. Jacobsen Sells 24,000 Shares - June 15 at 10:26 PM logoOmeros Co. (OMER) Earns "Strong-Buy" Rating from WBB Securities - June 14 at 1:00 PM logoOmeros Corporation's (OMER) "Ourperform" Rating Reiterated at Wedbush - June 14 at 7:56 AM logoOmeros (OMER) OMS721 Granted FDA Breakthrough Therapy Designation - June 13 at 7:08 PM logoHere's Why Omeros Corporation Stock Rose as Much as 16.7% Today - June 13 at 7:07 PM logoFDA Grants Breakthrough Therapy Designation to Omeros’ MASP-2 Inhibitor OMS721 for the Treatment of IgA Nephropathy - June 13 at 7:07 PM logoETFs with exposure to Omeros Corp. : June 13, 2017 - June 13 at 7:07 PM logoHere's Why Omeros Corporation Stock Rose as Much as 16.7% Today - June 13 at 7:07 PM logoOmeros Corporation’s Breakthrough Becomes a Clear Danger to Alexion: WBB - June 13 at 7:07 PM logoOmeros Corporation (OMER) Receives Consensus Recommendation of "Buy" from Analysts - June 13 at 5:04 PM logoCantor Fitzgerald's Piros Still Isn't A Buyer Of Omeros After Tuesday's FDA Win - June 13 at 1:34 PM logoToday's Research Reports on Stocks to Watch: Coherus Biosciences and Omeros Corporation - June 13 at 10:39 AM logoOmeros Corp. breached its 50 day moving average in a Bullish Manner : OMER-US : June 13, 2017 - June 13 at 10:39 AM logoOmeros (OMER) Worth a Look: Stock Adds 11.8% in Session - June 13 at 10:39 AM logoPlasminogen Market by Intravenous Injection, Eye drops Types, Application, 4 Manufacturers Analysis and 2022 Forecast at - June 12 at 12:22 AM logoOmeros: Can the Growth Story Continue? - June 7 at 10:11 AM logo$15.81 Million in Sales Expected for Omeros Co. (OMER) This Quarter - June 4 at 8:40 AM logoOmeros Co. (OMER) Rating Reiterated by Cowen and Company - June 3 at 9:32 PM logoOmeros Co. (OMER) Upgraded to "Hold" by ValuEngine - June 3 at 7:38 PM logo Brokerages Expect Omeros Co. (OMER) to Post -$0.33 EPS - June 2 at 2:34 PM



Omeros Corporation (OMER) Chart for Friday, July, 21, 2017

This page was last updated on 7/21/2017 by Staff